GVR Report cover Diabetes Devices Market Size, Share & Trends Report

Diabetes Devices Market Size, Share & Trends Analysis Report By Type (BGM Devices, Insulin Delivery Devices), By Distribution Channel, By End-use (Hospitals, Homecare), By Region, And Segment Forecasts, 2021 - 2028

  • Published Date: Jul, 2021
  • Base Year for Estimate: 2020
  • Report ID: 978-1-68038-873-2
  • Format: Electronic (PDF)
  • Historical Data: 2016 - 2019
  • Number of Pages: 140

Report Overview

The global diabetes devices market size was valued at USD 25.9 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 6.6% from 2021 to 2028. The market is primarily driven by factors such as an increase in technological advancements and rise in the incidence of obesity. Moreover, the increasing adoption of insulin delivery devices and the rising prevalence of diabetes are driving market growth.

North America diabetes devices market size, by end-use, 2018 - 2028 (USD Billion)

Individuals diagnosed with diabetes are at an increased risk for COVID-19, thereby accelerating the demand for diabetes devices to effectively manage patients in the hospital as well as home care settings. The increasing demand for diabetes devices is attributed to preventing longer hospital stays and higher mortality rates in diabetic patients. In response to the urgency brought about due to the pandemic, the U.S. Food and Drug Administration (FDA) issued guidance to permit the usage of home-use devices in hospital settings. This ensured the safety of healthcare workers by minimizing patient interactions. Thus, the adoption of diabetes devices amid COVID-19 was critical in managing the patients, thereby reducing the total healthcare expenditure mainly in resource-constrained settings.

An increase in the incidence of diabetes due to aging, obesity, and an unhealthy lifestyle is one of the factors contributing to the growth of the market. Obesity is a major factor leading to diabetes. According to the WHO, in 2016, over 1.9 billion adults were overweight, of which, around 650 million people were obese. Risk factors, such as obesity and overweight, are leading to an increase in the incidence of diabetes. Therefore, risk factors such as smoking, overweight, obesity, and high cholesterol levels are expected to boost the prevalence of diabetes, thus fueling the need for diabetes devices.

The number of people suffering from diabetes in regions such as MEA and APAC is increasing, which in turn is propelling the demand for diabetes treatment. For instance, as per the International Diabetes Federation, in 2017, 72,946,400 new cases of diabetes were diagnosed in India. Thus, the presence of untapped growth opportunities in rapidly growing MEA and Asian economies and growing awareness of diabetes in these regions are anticipated to boost the demand for diabetes devices. The large geriatric population, affordable healthcare facilities, cost-efficient labor, and relatively less stringent regulatory policies are among the factors compelling diabetic devices manufacturers to expand their businesses. The manufacturers are now focusing on leveraging opportunities present in developing economies to gain maximum market share.

Technological advancements in diabetes devices such as the introduction of high-end insulin pumps and pens are propelling the demand for these products. Leading manufacturers are focusing on technological innovations and the development of advanced products to gain a substantial share of the market. In February 2019, Abbott entered into a non-exclusive partnership with Novo Nordisk. This partnership is expected to help in enhancing digital solutions for diabetes. Under this partnership, the data captured by Novo Nordisk prefilled durable connected pens will be reflected in digitally connected FreeStyle Libre system through FreeStyle LibreLink mobile app and LibreView cloud-based system. Through this technological integration, healthcare professionals can analyze both glucose and insulin data together, which in turn is likely to simplify diabetes management.

Type Insights

The insulin delivery devices segment dominated the market and accounted for the largest revenue share of over 56.0% in 2020. On the basis of insulin delivery devices, the market has been segmented into pens, pumps, syringes, and jet injectors. Pens held the larger share of the market in 2020. However, the pump segment is expected to gain substantial market share as it is estimated to witness a CAGR of 8.0% during the forecast period.

Based on type, the market is segmented into blood glucose monitoring devices and insulin delivery devices. Blood glucose monitoring devices are further segmented into self-monitoring devices and continuous glucose monitoring devices.

The adoption of blood glucose meters is gradually increasing due to their various advantages such as portability and accuracy. Market players are also focusing on developing these devices and are introducing small blood glucose meters. Some of the smallest blood glucose meters with advanced technology available in the U.K. are Abbott Diabetes Care Freestyle Lite, Bayer’s CONTOUR NEXT USB, Lifescan’s One Touch UltraEasy, Accu-Chek Aviva Nano, Accu-Chek Mobile, and TRUEone blood glucose meter. Introduction of these small, discreet, and easy-to-use blood glucose meters is expected to boost the segment growth during the forecast period.

Distribution Channel Insights

The hospital pharmacies segment dominated the market and accounted for the largest revenue share of over 54.0% in 2020 owing to high footfall and availability of products. Other distribution channels include retail pharmacies, diabetes clinics/ centers, and online pharmacies.

The two types of pharmacies operating within a hospital campus are inpatient pharmacy and outpatient pharmacy. Inpatient pharmacy is present within the hospital, accessible only by authorized personnel serving operation rooms, ICU, inpatient wards, and special service areas. Whereas, outpatient pharmacies are generally located in hospital lobbies and entrances, for customers. Handheld glucose meters and insulin delivery devices are available at the outpatient pharmacy.

As online pharmacies directly procure diabetes devices from the manufacturers, it helps them avail lucrative deals for customers. The increasing patient awareness about online pharmacies and increased public-private funding are key factors driving the segment. The COVID-19 pandemic has positively impacted the e-pharmacies business; the sales volume of diabetes devices is observed to have increased through this platform.

End-use Insights

The hospital segment dominated the market and accounted for the largest revenue share of more than 40.0% in 2020. An increasing number of hospital admissions of diabetes patients is boosting the demand for the segment. Patients suffering from diabetes have a threefold chance of hospitalization compared with those without diabetes. Diabetes technology has evolved rapidly in the past few years. Most of these technologies aim to improve diabetes care in hospitals and clinics. These advancements in technology have increased the usage of insulin pumps in hospitals and clinics.

Global diabetes devices market share, by end-use, 2020 (%)

The homecare segment is anticipated to witness a CAGR of 7.2% over the forecast period. This growth is attributed to growing awareness about diabetes preventive care. Increasing government initiatives to promote awareness about diabetes and the user-friendly interface of insulin pumps are increasing the demand for insulin pumps in the homecare settings. Moreover, the increasing geriatric population is boosting the demand for homecare. According to WHO, 80% of the total elder population are living in low- and middle-income countries. By 2050, the total population aged 60 and older is expected to reach 2 billion. Thus, the abovementioned factors are boosting the demand for insulin pumps in homecare settings, which is expected to witness an exponential growth rate.

Regional Insights

North America dominated the diabetes devices market and accounted for the largest revenue share of 39.3% in 2020. The region is expected to lead the market with a growth rate of over 6.0% over the forecast period owing to its well-established healthcare sector. Increasing prevalence of obesity and the high cost of treatment is also expected to drive the region, along with technological advancements and new product launches.

In North America, the U.S. dominated the market owing to a large diabetic population and favorable reimbursement policies. High per capita income and increasing healthcare spending are among the key factors driving its market. According to the American Diabetes Association, the total cost of diagnosed diabetes in 2017 was USD 327.0 billion. In the U.S., people with diagnosed diabetes incur an average medical expenditure of USD 16,750 per year.

The adoption rate of insulin delivery devices in Asian countries, such as China and India, is high. Factors such as growing awareness about diabetes care and an evolving healthcare landscape are responsible for the higher adoption of these devices in the APAC countries. In addition, the rise in healthcare spending has led to an increase in the adoption of technologically advanced products in countries such as China and India, and is expected to boost the overall market growth.

Key Companies & Market Size Insights

Market leaders are focusing on product launches and technological collaboration to increase their foothold in the market. For instance, in November 2020, Novo Nordisk announced the acquisition of Emisphere Technologies—a drug delivery technology company. The acquisition is anticipated to help Novo Nordisk gain a competitive edge in the oral antidiabetic market. Some of the prominent players in the diabetes devices market include:

  • Medtronic plc

  • Abbott Laboratories

  • F.Hoffmann-La-Ltd.

  • Bayer AG

  • Lifescan, Inc.

  • B Braun Melsungen AG

  • Lifescan, Inc.

  • Dexcom Inc.

  • Insulet Corporation

  • Ypsomed Holdings

  • Companion Medical

  • Sanofi

  • Valeritas Holding Inc.

  • Novo Nordisk

  • Arkray, Inc.

Diabetes Devices Market Report Scope

Report Attribute


Market size value in 2021

USD 28.5 billion

Revenue forecast in 2028

USD 44.6 billion

Growth Rate

CAGR of 6.6% from 2021 to 2028

Base year for estimation


Historical data

2016 - 2019

Forecast period

2021 - 2028

Quantitative units

Revenue in USD million and CAGR from 2021 to 2028

Report coverage

Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Segments covered

Type, distribution channel, end-use, region

Regional scope

North America; Europe; Asia Pacific; Latin America; Middle East & Africa (MEA)

Country scope

U.S., Canada; U.K.; Germany; France; Italy; Spain; Czech Republic; Russia; Poland; Turkey; Switzerland; Japan; China; India; Thailand; South Korea; Australia; Vietnam; Philippines; Malaysia; Indonesia; Brazil; Mexico; Chile;  Argentina; Colombia; South Africa; Saudi Arabia; UAE; Egypt; Oman

Key companies profiled

Medtronic plc; Abbott Laboratories; F.Hoffmann-La-Ltd.; Bayer AG; Lifescan, Inc.; B Braun Melsungen AG; Lifescan, Inc.; Dexcom Inc.; Insulet Corporation; Ypsomed Holdings; Companion Medical; Sanofi; Valeritas Holding Inc.; Novo Nordisk; Arkray, Inc.

Customization scope

Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2028. For the purpose of this study, Grand View Research has segmented the global diabetes devices market report on the basis of type, distribution channel, end-use, and region:

  • Type Outlook (Revenue, USD Million, 2016 - 2028)

    • BGM Devices

      • Self-Monitoring Devices

        • Blood Glucose Meters

        • Testing Strips

        • Lancets

      • Continuous Glucose Monitoring Devices

        • Sensors

        • Transmitters

        • Receiver

    • Insulin Delivery Devices

      • Pumps

      • Pens

      • Syringes

      • Jet Injectors

  • Distribution Channel Outlook (Revenue, USD Million, 2016 - 2028)

    • Hospital pharmacies

    • Retail Pharmacies

    • Diabetes Clinics/Centers

    • Online Pharmacies

    • Others

  • End-use Outlook (Revenue, USD Million, 2016 - 2028)

    • Hospitals

    • Homecare

    • Diagnostic Centers

  • Regional Outlook (Revenue, USD Million, 2016 - 2028)

    • North America

      • U.S.

      • Canada

    • Europe

      • U.K.

      • Germany

      • France

      • Spain

      • Italy

      • Russia

      • Czech Republic

      • Poland

      • Switzerland

      • Turkey

    • Asia Pacific

      • Japan

      • China

      • India

      • Australia

      • Vietnam

      • Philippines

      • Malaysia

      • Indonesia

      • Thailand

      • South Korea

    • Latin America

      • Brazil

      • Mexico

      • Argentina

      • Chile

      • Colombia

    • Middle East & Africa

      • South Africa

      • Saudi Arabia

      • UAE

      • Egypt

      • Oman

Frequently Asked Questions About This Report

gvr icn


gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself...

gvr icn


We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

BBB icon D&B icon

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.